NCT04079738 2023-09-13Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor IxazomibBig Ten Cancer Research ConsortiumPhase 1/2 Terminated8 enrolled 10 charts
NCT02323113 2023-02-08Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)Calithera Biosciences, IncPhase 1/2 Terminated43 enrolled 27 charts